Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin
about
The key role of genomics in modern vaccine and drug design for emerging infectious diseasesHigh yield production process for Shigella outer membrane particlesPhase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles.Review of meningococcal group B vaccines.Impaired immunogenicity of a meningococcal factor H-binding protein vaccine engineered to eliminate factor h binding.Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from AfricaModulation of endotoxicity of Shigella generalized modules for membrane antigens (GMMA) by genetic lipid A modifications: relative activation of TLR4 and TLR2 pathways in different mutantsThe effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein.Cysteine depletion causes oxidative stress and triggers outer membrane vesicle release by Neisseria meningitidis; implications for vaccine developmentMutant Native Outer Membrane Vesicles Combined with a Serogroup A Polysaccharide Conjugate Vaccine for Prevention of Meningococcal Epidemics in Africa.Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys.A critical threshold of meningococcal factor H binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccinesA native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice.Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development.A naturally derived outer-membrane vesicle vaccine protects against lethal pulmonary Burkholderia pseudomallei infection.The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens.Impaired Immunogenicity of Meningococcal Neisserial Surface Protein A in Human Complement Factor H Transgenic Mice.Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2Does binding of complement factor H to the meningococcal vaccine antigen, factor H binding protein, decrease protective serum antibody responses?Genetically modified L3,7 and L2 lipooligosaccharides from Neisseria meningitidis serogroup B confer a broad cross-bactericidal response.Meningococcal Outer Membrane Vesicle Composition-Dependent Activation of the Innate Immune Response.A Meningococcal Outer Membrane Vesicle Vaccine Incorporating Genetically Attenuated Endotoxin Dissociates Inflammation from Immunogenicity.Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future.Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines.Neisseria meningitidis B vaccines: recent advances and possible immunization policies.Biosynthetically engineered lipopolysaccharide as vaccine adjuvant.Cell membrane-derived nanomaterials for biomedical applications.Novel approaches to Neisseria meningitidis vaccine design.Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37.The development of an experimental multiple serogroups vaccine for Neisseria meningitidis.A deeper mining on the protein composition of VA-MENGOC-BC®: An OMV-based vaccine against N. meningitidis serogroup B and C.
P2860
Q28476274-8B45E749-CEF4-4765-8110-CBED9C486023Q28728768-DCCDB974-0A03-4F53-B7EA-6D73360C7C07Q30227840-6BF99F2A-EF3F-4219-992F-99FD8E6CBDF5Q33646965-1F43211A-D54C-4396-8196-4882067EAB94Q33962709-D1A80B9D-B00F-4865-BCFE-A8E8684581ADQ34039044-C20B4C3B-B4CC-44CC-9EB7-5A6C87B15793Q34138990-791BD01B-2078-4402-A986-42C8F3B82B90Q34270429-4A00687A-2D10-45BC-BA34-61C0B8A33F94Q34571107-CC62747F-D8E1-42FA-8DC9-66F398A6918AQ34785389-35178E3B-C6B5-498D-9831-CCA213B6E6D8Q35043042-DA97E375-1E25-4ABD-B398-8CDF53EF7476Q35066132-DAE9B37C-7CCB-4A65-8BA3-F1A8F0111D10Q35181636-E372BE85-A65D-4429-B950-A4F445632229Q35198778-243483CC-761E-49D2-BB5F-5DE78E4E570AQ35375333-0A33618B-070A-46E7-BD3E-B0FCD5BAC7E7Q35989852-7BA1F039-E95F-45B1-B617-A7954522C16EQ36513433-460FEFCF-324D-48CB-86CA-678528B41CE0Q37099232-55EE0BC3-360A-47D4-A034-2870EF73C911Q37124721-BB6B1143-448E-4FEA-914E-0F037FF65FFEQ37191328-77F57E9F-6809-46E3-89BE-1E222AE63C49Q37287207-5A92BF69-E766-4BFB-BE34-B30AA7BF4BC2Q37483629-DCBF207A-A506-45B4-9952-932455FDE843Q37514748-9268FEEB-DCB5-4B82-820E-0FB30EF7CBA0Q37857249-FB38F649-5CB8-4E41-B401-CD89EA0E84A0Q38183156-A5B02528-F858-4EFC-9CCD-E6FD49EEC709Q38386726-8FFD3C4F-EC91-4238-895D-8B4EFB1836EFQ39178313-4CE5417D-B0EF-4262-81EB-2DE72B65C2B1Q39215403-F9D1F598-5CEE-4083-A6F7-F66986477615Q41825787-765338F0-6819-4D90-9C8D-4BDF1B53C173Q42131377-251CEB99-1E99-440E-BC51-F51B16FA1F89Q46272338-7C74EA65-5692-437A-A1E0-9608BDB26EA9
P2860
Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bactericidal antibody response ...... netically attenuated endotoxin
@en
Bactericidal antibody response ...... etically attenuated endotoxin.
@nl
type
label
Bactericidal antibody response ...... netically attenuated endotoxin
@en
Bactericidal antibody response ...... etically attenuated endotoxin.
@nl
prefLabel
Bactericidal antibody response ...... netically attenuated endotoxin
@en
Bactericidal antibody response ...... etically attenuated endotoxin.
@nl
P2860
P921
P356
P1476
Bactericidal antibody response ...... netically attenuated endotoxin
@en
P2093
Dan M Granoff
Oliver Koeberling
P2860
P304
P356
10.1086/589308
P407
P50
P577
2008-07-01T00:00:00Z